Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AC Immune (ACIU) Invested Capital: 2014-2025

Historic Invested Capital for AC Immune (ACIU) over the last 9 years, with Sep 2025 value amounting to $78.1 million.

  • AC Immune's Invested Capital fell 48.04% to $78.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.1 million, marking a year-over-year decrease of 48.04%. This contributed to the annual value of $78.1 million for FY2025, which is N/A change from last year.
  • Per AC Immune's latest filing, its Invested Capital stood at $78.1 million for Q3 2025, which was down 13.54% from $90.3 million recorded in Q2 2025.
  • AC Immune's 5-year Invested Capital high stood at $229.4 billion for Q1 2021, and its period low was $23.2 million during Q4 2024.
  • For the 3-year period, AC Immune's Invested Capital averaged around $128.3 million, with its median value being $142.3 million (2023).
  • As far as peak fluctuations go, AC Immune's Invested Capital spiked by 83,530.55% in 2021, and later crashed by 99.90% in 2022.
  • AC Immune's Invested Capital (Quarterly) stood at $275.1 million in 2021, then crashed by 31.26% to $189.1 million in 2022, then increased by 5.49% to $199.4 million in 2023, then slumped by 88.38% to $23.2 million in 2024, then plummeted by 48.04% to $78.1 million in 2025.
  • Its Invested Capital stands at $78.1 million for Q3 2025, versus $90.3 million for Q2 2025 and $105.4 million for Q1 2025.